NO20052426L - Fremgangsmater for vaksinasjon mot malaria - Google Patents

Fremgangsmater for vaksinasjon mot malaria

Info

Publication number
NO20052426L
NO20052426L NO20052426A NO20052426A NO20052426L NO 20052426 L NO20052426 L NO 20052426L NO 20052426 A NO20052426 A NO 20052426A NO 20052426 A NO20052426 A NO 20052426A NO 20052426 L NO20052426 L NO 20052426L
Authority
NO
Norway
Prior art keywords
methods
against malaria
vaccination against
based vaccine
protein
Prior art date
Application number
NO20052426A
Other languages
English (en)
Other versions
NO20052426D0 (no
Inventor
Joseph Cohen
Stephen L Hoffman
Ruobing Wang
Judith E Epstein
Original Assignee
Us Navy Naval Med Res Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Navy Naval Med Res Ct filed Critical Us Navy Naval Med Res Ct
Publication of NO20052426L publication Critical patent/NO20052426L/no
Publication of NO20052426D0 publication Critical patent/NO20052426D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelsen angår fremgangsmåter for beskyttelse mot malariainfeksjon ved vaksinasjon. Fremgangsmåten ifølge oppfinnelsen innbefatter å prime en antimalaria immunreaksjon med en DNA-basert vaksine og forsterke reaksjonen med en proteinbasert vaksine. Fremgangsmåten ifølge oppfinnelsen angår også en utvidelse av den resulterende i mmunreaksjonen ved en forsterkning med en proteinbasert vaksine.
NO20052426A 2002-10-23 2005-05-19 Fremgangsmater for vaksinasjon mot malaria NO20052426D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42026502P 2002-10-23 2002-10-23
US44702603P 2003-02-13 2003-02-13
PCT/US2003/033462 WO2004037189A2 (en) 2002-10-23 2003-10-22 Methods for vaccinating against malaria

Publications (2)

Publication Number Publication Date
NO20052426L true NO20052426L (no) 2005-05-19
NO20052426D0 NO20052426D0 (no) 2005-05-19

Family

ID=32179789

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052426A NO20052426D0 (no) 2002-10-23 2005-05-19 Fremgangsmater for vaksinasjon mot malaria

Country Status (11)

Country Link
US (1) US8232255B2 (no)
EP (2) EP1569515A4 (no)
JP (2) JP5404990B2 (no)
AU (2) AU2003285932A1 (no)
CA (1) CA2502268A1 (no)
ES (1) ES2594758T3 (no)
NO (1) NO20052426D0 (no)
NZ (1) NZ539509A (no)
PL (1) PL376792A1 (no)
RU (1) RU2356577C9 (no)
WO (1) WO2004037189A2 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672290B1 (fr) * 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
NZ532383A (en) 2001-11-21 2007-03-30 Univ Pennsylvania Pan-7 simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US8232255B2 (en) * 2002-10-23 2012-07-31 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
KR101253363B1 (ko) 2004-10-13 2013-04-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 개선된 아데노바이러스 벡터 및 그것의 용도
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
MX2009000650A (es) 2006-07-18 2009-07-02 Secretary Of The Army The Unit Vacunas para malaria.
US8400408B2 (en) * 2007-06-13 2013-03-19 Apple Inc. Touch screens with transparent conductive material resistors
NZ583150A (en) 2007-08-13 2012-05-25 Glaxosmithkline Biolog Sa Use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum in the manufacture of a medicament for vaccinating infants against malaria
TW200938633A (en) * 2007-12-06 2009-09-16 Glaxosmithkline Biolog Sa Vaccine
BRPI0905729A2 (pt) * 2008-01-18 2015-07-14 Aeras Global Tb Vaccine Found "polipeptídeo antigênico recombinante, peptídeo antigênico recombinante, ácido nucléico e método para imunizar um indivíduo contra malária"
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2011022002A1 (en) * 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
EP2470554B1 (en) * 2009-08-26 2017-06-28 Selecta Biosciences, Inc. Compositions that induce t cell help
US20110117120A1 (en) * 2009-11-13 2011-05-19 Martha Sedegah Plasmodium falciparum HLA class I restricted T-cell epitopes
MX354752B (es) * 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
US9115205B2 (en) 2010-10-18 2015-08-25 The United States Of America, As Represented By The Secretary Of The Army Plasmodium falciparum circumsporozoite vaccine gene optimization for soluble protein expression
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
WO2014028644A1 (en) * 2012-08-15 2014-02-20 Cyvax, Inc. Methods and compositions for preventing a condition
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
JPWO2016059911A1 (ja) * 2014-10-17 2017-07-27 国立大学法人金沢大学 マラリアワクチン
EP3442570A1 (en) 2016-04-12 2019-02-20 Oxford University Innovation Limited Prime target
JP2017210441A (ja) * 2016-05-26 2017-11-30 国立大学法人大阪大学 マラリアワクチン
EA202091074A1 (ru) 2017-10-31 2020-07-22 Янссен Вэксинс Энд Превеншн Б.В. Аденовирус и его применения
KR20200083510A (ko) 2017-10-31 2020-07-08 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도
KR20200074987A (ko) 2017-10-31 2020-06-25 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도
CA3077630A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
AU2927892A (en) 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
US5928902A (en) 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
PL178578B1 (pl) 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania
BR9408071A (pt) 1993-11-17 1996-12-24 Om Lab Sa Di-sacarideos de glucosamina processo para sua preparação e composição farmacêutica que compreende os mesmos e seu uso
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
US6645495B1 (en) 1997-08-29 2003-11-11 Antigenics, Inc. Compositions of saponin adjuvants and excipients
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US7014864B1 (en) * 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
NZ532383A (en) 2001-11-21 2007-03-30 Univ Pennsylvania Pan-7 simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
AU2002360429A1 (en) 2001-11-26 2003-06-10 Avigen, Inc. Methods for producing stocks of recombinant aav virions
US8232255B2 (en) * 2002-10-23 2012-07-31 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
US20050208078A1 (en) * 2003-11-20 2005-09-22 Hoffman Stephen L Methods for the prevention of malaria

Also Published As

Publication number Publication date
EP1569515A4 (en) 2006-04-26
EP2277533B1 (en) 2016-07-20
ES2594758T3 (es) 2016-12-22
RU2005115837A (ru) 2006-01-20
NO20052426D0 (no) 2005-05-19
EP1569515A2 (en) 2005-09-07
AU2003285932A1 (en) 2004-05-13
JP5404990B2 (ja) 2014-02-05
RU2356577C2 (ru) 2009-05-27
JP2006512405A (ja) 2006-04-13
WO2004037189A2 (en) 2004-05-06
WO2004037189A3 (en) 2004-10-21
PL376792A1 (pl) 2006-01-09
EP2277533A3 (en) 2012-03-07
JP2011068671A (ja) 2011-04-07
US8232255B2 (en) 2012-07-31
EP2277533A2 (en) 2011-01-26
US20060188527A1 (en) 2006-08-24
AU2010200177A1 (en) 2010-02-04
RU2356577C9 (ru) 2009-08-10
NZ539509A (en) 2008-05-30
CA2502268A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
NO20052426L (no) Fremgangsmater for vaksinasjon mot malaria
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
NO20051469L (no) Immunstimulerende nukleinsyrer.
DE60024112D1 (de) Influenzavirus-impfstoffzusammensetzung
CY1112749T1 (el) Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
NO20024246D0 (no) Endret stamme av det modifiserte vacciniaviruset (Ankara MVA)
MXPA04000680A (es) Vacuna para virus west nile.
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
NO20090178L (no) Vaksiner for malaria
WO2000067787A3 (en) Hiv immunogenic compositions and methods
WO2004004654A3 (en) Vaccines to induce mucosal immunity
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
DE60226175D1 (de) Mycobakterieller impfstoff
WO2022137128A3 (en) Self-amplifying messenger rna
NO20051840L (no) IHNV G-protein til immunstimulering.
MXPA05012270A (es) Materiales y metodos para inmunizar en contra de la infeccion por virus de inmunodeficiencia de felino.
WO2003080112A3 (en) Imidazoquinolineamines as adjuvants in hiv dna vaccination
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
CA2457804A1 (en) Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
WO2005027844A3 (en) Dna vaccine compositions and methods of use
DK1554383T3 (da) Rekombinante MVA-stammer som potentieller vacciner mod P. falciparum-malaria
DE60233391D1 (de) Vakzine zum schutz von tieren gegen leishmania
WO2004034956A3 (de) 8-plasmid methode mit mutiertem ha gen zur herstellung eines influenza-impfstoffes
ZA200201357B (en) Vaccine against intra-cellular pathogens.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application